Company
Ocugenix
A Disease-Modifying Approach to Wet AMD, Geographic Atrophy, and Diabetic Retinopathy
Also known as OCUGENIX CORP
- Status
- Operatingas of 2026-09-18
- Business model
- B2B
- Legal name
- OCUGENIX CORP
Claim, correct or request removal
Record updated 28 September 2026
About
Through discoveries of the molecular mechanisms of wound healing, Ocugenix has identified molecular pathways that, when activated, initiate the natural wound healing processes, leading to the complete resolution of inflammation and restoration of homeostasis. Several eye diseases result from this breakdown in the wound healing process. It is these diseases in the eye, all with significant unmet needs, that Ocugenix is dedicated to addressing.
Funding snapshot
- Total raised
- $1.6MSEC form D sum, as of 2026-09-28Source (opens in a new tab)
- Latest round
- Round, $1.3M2021-07-08
Funding rounds
- Round, 2021
- $1.3M2021-07-08, SEC form D sold, 8 investors
- Round, 2019
- $350K2019-08-31, SEC form D sold, 6 investors
Products
- Other
- OGX-110
Loading relationship preview